Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

NCT05551117 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT05551117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05551117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Lead sponsor
MacroGenics
Phase
Phase 2
Overall status
Terminated
Start date
June 13, 2023
Completion date
January 23, 2025
Enrollment
192 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, anal neoplasm, androgen-independent prostatic cancer, androgen-insensitive prostatic cancer, androgen-resistant prostatic cancer, carcinoma, squamous cell of head and neck, castration-resistant prostatic cancer, head and neck squamous cell carcinoma, hormone refractory prostatic cancer, laryngeal squamous cell carcinoma, malignant melanoma, melanoma, non-small cell carcinoma, non-small cell lung cancer, oral squamous cell carcinoma, small cell carcinoma, small-cell lung cancer